Last reviewed · How we verify
Tacrolimus with Methotrexate
Tacrolimus with Methotrexate is a Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently FDA-approved. Also known as: TacroBell® with MTX.
Tacrolimus is a small molecule inhibitor of the FK506-binding protein 1A, which is involved in the mechanism of action. It is used in combination with methotrexate to treat conditions such as Graft vs Host Disease, Malignancy, Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, and Adult Acute Monoblastic Leukemia.
At a glance
| Generic name | Tacrolimus with Methotrexate |
|---|---|
| Also known as | TacroBell® with MTX |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (PHASE2)
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies (PHASE3)
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes (PHASE2)
- Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tacrolimus with Methotrexate CI brief — competitive landscape report
- Tacrolimus with Methotrexate updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI
Frequently asked questions about Tacrolimus with Methotrexate
What is Tacrolimus with Methotrexate?
Who makes Tacrolimus with Methotrexate?
Is Tacrolimus with Methotrexate also known as anything else?
What development phase is Tacrolimus with Methotrexate in?
Related
- Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
- Also known as: TacroBell® with MTX
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing